Search

Your search keyword '"MESH: HIV-1 / isolation & purification"' showing total 2 results
Start Over Descriptor "MESH: HIV-1 / isolation & purification" Search Limiters Full Text
2 results on '"MESH: HIV-1 / isolation & purification"'

1. IL-7 immunotherapy for progressive multifocal leukoencephalopathy in a patient with already controlled HIV-1 infection on antiretroviral therapy

Author

Fabrice Bonneville, Stella Rousset, Guillaume Martin-Blondel, Pierre Delobel, Yassine Taoufik, Marie Guille, Catherine Mengelle, Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service Neuroradiologie Diagnostique et Thérapeutique [CHU Toulouse], Pôle imagerie médicale [CHU Toulouse], Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Oncology, medicine.medical_specialty, medicine.medical_treatment, viruses, MESH: Leukoencephalopathy, Progressive Multifocal / diet therapy, Immunology, Treatment outcome, Human immunodeficiency virus (HIV), MESH: HIV Infections / complications, MESH: HIV Infections / drug therapy, medicine.disease_cause, MESH: Magnetic Resonance Imaging, Leukoencephalopathy, MESH: HIV-1 / isolation & purification, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, medicine, Immunology and Allergy, MESH: Treatment Outcome, MESH: Anti-Retroviral Agents / administration & dosage, MESH: Humans, MESH: Middle Aged, medicine.diagnostic_test, MESH: Plasma / virology, business.industry, MESH: Interleukin-7 / administration & dosage, Progressive multifocal leukoencephalopathy, virus diseases, Magnetic resonance imaging, Immunotherapy, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, medicine.disease, Antiretroviral therapy, MESH: Immunotherapy / methods, MESH: Immunologic Factors / administration & dosage, Infectious Diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, MESH: JC Virus / isolation & purification, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: Brain / diagnostic imaging, MESH: Brain / pathology, business, MESH: Viral Load, Viral load, MESH: Cerebrospinal Fluid / virology, MESH: Female
Abstract

International audience; The incidence of progressive multifocal leukoencephalopathy (PML) among patients living with HIV (PML-HIV) decreased in the antiretroviral therapy (ART) era. JC virus (JCV) infection of the brain remains a devastating disease. Given the lack of drugs controlling JCV, initiation of ART and subsequent recovery of JCV-specific CD4+ and CD8+ T-cell immune responses remain the only therapeutic option. Although the 1-year survival rate increased from 10% to 50%, other strategies are required.

Published
2019

2. Once‐daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS ‐165 DARULIGHT study

Author

François Raffi, Jean-Michel Molina, Christine Katlama, Marie-Laure Chaix, Juliette Saillard, Minh Patrick Lê, Gilles Peytavin, Sylvie Chevret, Sebastien Gallien, Yazdan Yazdanpanah, Pierre Delobel, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie [CHU Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Hopital Saint-Louis [AP-HP] (AP-HP), Service de biostatistique et information médicale de l’hôpital Saint Louis (Equipe ECSTRA) (SBIM), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut national du cancer [Boulogne] (INCA)-Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP, Hôpital Henri-Mondor Albert-Chenevier, Service d'Immunologie Clinique et Maladies Infectieuses 94000 Créteil, France, Service de Maladies Infectieuses et Tropicales [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service Maladies infectieuses et tropicales [CHU Toulouse], Pôle Inflammation, infection, immunologie et loco-moteur [CHU Toulouse] (Pôle I3LM Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Services de Maladies Infectieuses et Tropicales [CHU Bichat], ANRS France Recherche Nord & sud Sida-hiv hépatites, Service des Maladies Infectieuses et Tropicales [CHU Saint Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Pistre, Karine

Subjects
Darunavir+Ritonavir, unbound total, [SDV.IMM] Life Sciences [q-bio]/Immunology, [SDV]Life Sciences [q-bio], MESH: HIV Infections / drug therapy, MESH: Darunavir / pharmacokinetics, darunavir, Pharmacology, MESH: Drug Administration Schedule, MESH: HIV-1 / drug effects, seminal and blood plasma, MESH: HIV Infections / blood, MESH: Dose-Response Relationship, Drug, MESH: HIV-1 / isolation & purification, medicine, MESH: HIV Infections / virology, Pharmacology (medical), Therapy efficacy, Letter to the Editor, Darunavir, MESH: Drug Combinations, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, business.industry, MESH: Drug Therapy, Combination / methods, MESH: Adult, Penetration (firestop), MESH: Darunavir / administration & dosage, MESH: HIV-1 / genetics, [SDV] Life Sciences [q-bio], MESH: HIV Protease Inhibitors / pharmacokinetics, dose reduction, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.IMM]Life Sciences [q-bio]/Immunology, Dose reduction, MESH: HIV Protease Inhibitors / administration & dosage, Once daily, business, medicine.drug
Abstract

International audience; A key concern for reduced-dose antiretroviral regimens in maintenance strategies in HIV-infected patients is virological efficacy, as assessed by the suppression of HIV-RNA in blood and reservoirs, such as the genital tract. The risk of minority variants emerging in reservoirs with different antiretroviral drug penetrations and immune pressures is also a matter of concern [1–4]. Thus, antiviral activity and drug penetration into deep compartments must be considered in reduced-dose strategies.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results